2007 (v1)
Publication
No description
Uploaded on: April 14, 2023
-
-
2012 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2008 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2011 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2011 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2011 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2010 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2012 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2009 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)PublicationSystems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial
Current colorectal cancer (CRC) treatment guidelines are primarily based on clinical features, such as cancer stage and grade. However, outcomes may be improved using molecular treatment guidelines. Potentially useful biomarkers include driver mutations and somatically inherited alterations, signaling proteins (their expression levels and...
Uploaded on: April 14, 2023 -
2009 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2009 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2010 (v1)Publication
The efficacy of anti-HER2 therapeutics, such as lapatinib and trastuzumab, is limited by primary and acquired resistance. Cellular adaptations that allow breast cancer cell to survive prolonged HER2 inhibition include de-repression of the transcription factor FOXO3A with consequent estrogen receptor activation, and/or increased HER3 signaling....
Uploaded on: April 14, 2023 -
2010 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2010 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2010 (v1)Publication
OBJECTIVE: The nicotinamide phosphoribosyltransferase (Nampt) inhibitor APO866 depletes intracellular nicotinamide adenine dinucleotide (NAD(+)) and shows promising anticancer activity in preclinical studies. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to plasma membrane receptors DR4 and DR5 and induces apoptosis via...
Uploaded on: April 14, 2023 -
2010 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2009 (v1)Publication
Nampt is a promising target for the treatment of hematological malignancies. Here, we investigated the cytotoxic activity of APO866, a potent, reversible Nampt inhibitor, in primary acute myelogenous leukemia and in chronic lymphocytic leukemia cells. 10 nM APO866 exhibited limited killing of primary leukemia cells with specific death rates...
Uploaded on: March 31, 2023 -
2009 (v1)Publication
Nicotinamide phosphoribosyltransferase (Nampt) inhibitors such as FK866 are potent inhibitors of NAD(+) synthesis that show promise for the treatment of different forms of cancer. Based on Nampt upregulation in activated T lymphocytes and on preliminary reports of lymphopenia in FK866 treated patients, we have investigated FK866 for its...
Uploaded on: October 11, 2023 -
2009 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2011 (v1)Publication
New derivatives of 1,4-dideoxy-1,4-imino-D-ribitol have been prepared and evaluated for their cytotoxicity on solid and haematological malignancies. 1,4-Dideoxy-5-O-[(9Z)-octadec-9-en-1-yl]-1,4-imino-Dribitol (13, IC50 similar to 2 mu M) and its C-18-analogues (IC50 < 10 mu M) are cytotoxic toward SKBR3 (breast cancer) cells. 13 also inhibits...
Uploaded on: March 31, 2023